ArticleFrontiers in oncology2025
Global and China burden and trend prediction of thyroid cancer attributed to high BMI from 1990 to 2021.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With economic development and lifestyle changes, the prevalence of obesity has increased significantly. However, limited research has investigated the trends in the burden of thyroid cancer attributable to high BMI. Methods: This study utilized data from the Global Burden of Disease (GBD 2021) study. Joinpoint regression analysis was used to compute the average annual percentage change (AAPC) in age-standardized disability-adjusted life year (DALY) rates (ASDR) and age-standardized mortality rates (ASMR). An age-period-cohort (APC) model was used to analyze the effects of age, period, and birth cohort on the burden of thyroid cancer attributable to high BMI. The ARIMA model was applied to predict the global and national disease burden from 2022 to 2031. Results: In 2021, the rates of change in DALY number, crude DALY rate, ASDR, death number, and crude death rate for thyroid cancer attributable to high BMI in China exceeded the corresponding global rates compared to 1990. From 1990 to 2021, the global burden of thyroid cancer attributable to high BMI was higher in women than in men, whereas in China, the burden was higher in men than in women from 2010 to 2021. The peak burden occurred in middle-aged populations, with the burden increasing with age. From 1990 to 2021, the ASDR and ASMR for thyroid cancer attributable to high BMI showed an upward trend globally and in China. Projections indicate that the burden will continue to rise from 2022 to 2031. Conclusion: From 1990 to 2021, the ASDR and ASMR for thyroid cancer attributable to high BMI exhibited an increasing trend globally and in China. The burden was higher in women than in men globally, but in China, it was higher in men than in women from 2010 to 2021. The burden increased with age. Projections suggest that the burden of thyroid cancer attributable to high BMI will continue to rise from 2022 to 2031.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.